Stocks making the biggest moves midday: Fannie Mae, Boston Scientific, Blackstone, Palo Alto Networks and more

Fannie Mae and Freddie Mac surged >30% after Bill Ackman called the stocks 'stupidly cheap' and suggested they could rise tenfold. Sysco plunged >11% after agreeing to buy Jetro Restaurant Depot for $29.1B TEV, while United Therapeutics jumped ~13% to a 52-week high on positive phase 3 Tyvaso data and plans for an FDA priority review. Alternative asset managers (Blackstone, Carlyle +4%+, Blue Owl, Apollo +3%+) rose after a DOL proposal easing 401(k) access to alternatives; Palo Alto jumped >7% after its CEO bought $10M of stock and Boston Scientific fell >9% on a Raymond James downgrade.

Analysis

The confluence of narrative-driven moves (celebrity investor commentary, CEO buybacks, analyst churn) with structural regulatory shifts (401(k) alt-asset proposal) is producing dispersion that favors fee-bearing, scale-driven franchises over capital-intensive distributors. Alternative managers with scalable fee curves and performance fees (BX, CG) can monetise a modest reweighting of retirement allocations: a 1% incremental AUM shift into alternatives drives high-teens percent EPS lift for some managers over 12–24 months given carried-interest gearing.

Cybersecurity is bifurcating around AI narrative risk: incumbents that demonstrate product adaptation to AI-driven threats (CRWD) can re-rate on TAM expansion, while firms with perceived displacement risk face extension of multiple contraction. Expect 2–3 quarters of elevated volatility as sell-side research tests AI sensitivity in models; near-term upgrades/downgrades will drive mechanically large intraday moves.

M&A and commodity shocks are creating asymmetric outcomes: large, debt-funded deals at low ROICs (distribution consolidation) are vulnerable to rising rates and working-capital shocks, whereas cyclical commodity winners (aluminum producers) can post sharply levered free-cash-flow improvements if price moves persist beyond one quarter. Clinical wins with Priority Review (biotech) compress binary timeline to ~6 months, concentrating FDA and commercial execution risk into a definable trading window.

Key Decisions for Investors

• Long BX and CG (6–12 months): overweight by +3–5% relative weight. Catalyst: incremental 401(k) alt flows and fund-raising tailwinds. Target: 20–30% total return if fee pools expand 1–2% AUM; stop-loss: 12% from entry to control political/regulatory backfire risk.
• Long CRWD via 3-month call spread (buy near-ATM 3-month calls / sell 30% OTM calls): capture re-rating from AI-driven demand; implied volatility hedge vs single-call buy. Risk/reward: cap upside ~2.5x premium; theta decay limited by spread construction. Close into two-stage analyst windows or on 15–20% move.
• Short SYY equity (3–9 months) size-constrained: thesis is deal leverage and integration execution compress cash conversion and equity multiple if markets reprice M&A financing. Target downside 20–30% if synergies slip or refinancing costs rise; tight stop at +15% on evidence of debt amortisation plans or asset sales.
• Long UTHR (6 months) or buy Jan-2027 calls: asymmetric payoff from label expansion under Priority Review. Probability-weighted upside: 40–60% if approval and uptake, downside 25–35% on safety/label setbacks. Manage with 20% trailing stop after 30% move.
• Tactical aluminum exposure (AA) via 3–6 month call spreads: exploit transient supply disruptions while capping premium. Target: 30–50% return on spread if LME stays elevated; unwind if prices revert >20% from peak or geopolitical tensions de-escalate.